A novel selective TNFR1 cyclic peptide engineered for cosmetic vehicles. Designed to interrupt the inflammatory cascade upstream of cytokine release, where prestige actives have never been able to reach.
The visible markers have been solved. Hydration, pigmentation, barrier, texture: mature categories, crowded shelves, incremental wins. Conglomerates are publicly investing in biotech and longevity science because the next decade of actives lives one layer beneath them.
That layer has no incumbent. It has no franchise. It has no consumer-known name. The first molecule that takes the receptor takes the category.
The molecule was conceived to act at the TNFR1 receptor with selectivity, in a cosmetic-grade vehicle, with a tolerability profile prestige skincare can actually deploy. It was engineered to fit the empty quadrant the rest of the category cannot reach.
TNFR1 · selective binding
Schematic. Receptor structures and binding mode are not to scale. Mechanism-of-action data, dose response, and binding affinity available under NDA.
Most molecules cannot tell them apart. Velryn was designed with that distinction at the centre. The selectivity is not a downstream observation. It is the design intent.
What this buys for the brand: the safety conversation does not require an asterisk. Tolerability is a feature of the molecule's design, not a separate marketing claim added later.
The honest position. We are not bringing you tolerability dressed as efficacy. We are bringing you a molecule with a designed mechanism, a cleared safety profile, and a study pathway you can shape with us.
Mechanism-level binding data, dose response, and ex-vivo signal are made available under NDA. → open the conversation
Discovery scientists Mark Currie and Neta Raab direct formulation. Brooke Willis evaluates each variant. Final candidate selected from this round.
The ingredient IP was developed by Sandcastle Biosciences. Altheya holds the commercial license to bring it to the cosmetic, dermatological, personal-care and OTC fields. Specific claim language and prosecution history are made available under NDA.
Domains secured: arve.co, arveskin.com, arvebeauty.com, arveintimate.com.
Co-inventor · Discovery
A career of receptor pharmacology that became approved medicine.
Discovery scientist whose foundational work on the guanylate cyclase-C pathway became Linzess. Basic science contributions sit beneath Celebrex, Dynastat, and Lunesta as well: the four together generating more than forty billion dollars in revenue.
Co-inventor · Strategy
A peptide-platform builder, extending biology into territory pharma has not yet mapped.
Co-founded Wild Biotech with Ido Bachelet (Harvard Church Lab) after four years collecting wild-animal microbiome samples across five continents. Foundational work published in Science. Backed by Marius Nacht.
An operator at the top of the company, with hands on every formula.
Chief Executive of Altheya, LLC. Holds the commercial relationship with Sandcastle Biosciences and the prestige licensing relationships in development. Named decision authority on partnership shape, brand framing, and the formulation candidate.
The brands below are illustrative examples drawn from the prestige cosmetic landscape. They show how the same molecule can carry four different stories depending on the franchise it anchors.
Across the prestige cosmetic landscape, the largest houses have invested visibly in next-generation cosmetic-actives infrastructure and senior R&D leadership over the past eighteen months. We are not telling anyone what they have signaled. We are observing that a platform like Velryn is the kind of asset that infrastructure was built for.
Altheya is in early conversations with a small number of prestige houses. The shape of partnership we are open to is the shape you would design: an exclusive licensing relationship, a co-development structure, or a sequenced engagement that begins with an NDA and a technical review.